Gardasil 9 joins the fight against cervix cancer

被引：44

作者：

Cuzick, Jack ^{[1
]}

机构：

[1] Queen Mary Univ London, Wolfson Inst Prevent Med, Ctr Canc Prevent, London EC1M 6BQ, England

来源：

EXPERT REVIEW OF VACCINES | 2015年 / 14卷 / 08期

关键词：

9-valent vaccine; cervical disease; Gardasil; human papilloma virus; vaccination; VACCINE;

D O I：

10.1586/14760584.2015.1051470

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

A trial of 14,215 women aged between 16 and 26 years comparing a new vaccine with nine human papilloma virus types - four from the licensed Gardasil vaccine (types 6, 11,16 and 18) and five new ones (types 31, 33, 45, 52 and 58) to Gardasil - has shown improved protection against cervical cancer precursor lesions. Antibody response for the four original Gardasil types was not inferior and a 96.3% reduction in high-grade cervical disease for the other five types not in Gardasil was seen in the per-protocol population. Six-month persistent infection was reduced by 96% for these types. There were no serious safety concerns, although injection site reactions were more common with the new vaccine.

引用

页码：1047 / 1049

页数：3

共 6 条

[1]

Bosch FX, 2013, VACCINE, V31, pI1, DOI DOI 10.1016/J.VACCINE.2013.07.026

[2] Individual detection of 14 high risk human papilloma virus genotypes by the PapType test for the prediction of high grade cervical lesions [J].

Cuzick, Jack ;

Ho, Linda ;

Terry, George ;

Kleeman, Michelle ;

Giddings, Michael ;

Austin, Janet ;

Cadman, Louise ;

Ashdown-Barr, Lesley ;

Costa, Maria J. ;

Szarewski, Anne .

JOURNAL OF CLINICAL VIROLOGY, 2014, 60 (01) :44-49

[3] Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases [J].

Garland, Suzanne M. ;

Hernandez-Avila, Mauricio ;

Wheeler, Cosette M. ;

Perez, Gonzalo ;

Harper, Diane M. ;

Leodolter, Sepp ;

Tang, Grace W. K. ;

Ferris, Daron G. ;

Steben, Marc ;

Bryan, Janine ;

Taddeo, Frank J. ;

Railkar, Radha ;

Esser, Mark T. ;

Sings, Heather L. ;

Nelson, Micki ;

Boslego, John ;

Sattler, Carlos ;

Barr, Eliav ;

Koutsky, Laura A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (19) :1928-1943

[4]

IARC, 2007, IARC MON EV CARC RIS, V80

[5] A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women [J].

Joura, E. A. ;

Giuliano, A. R. ;

Iversen, O-E ;

Bouchard, C. ;

Mao, C. ;

Mehlsen, J. ;

Moreira, E. D., Jr. ;

Ngan, Y. ;

Petersen, L. K. ;

Lazcano-Ponce, E. ;

Pitisuttithum, P. ;

Restrepo, J. A. ;

Stuart, G. ;

Woelber, L. ;

Yang, Y. C. ;

Cuzick, J. ;

Garland, S. M. ;

Huh, W. ;

Kjaer, S. K. ;

Bautista, O. M. ;

Chan, I. S. F. ;

Chen, J. ;

Gesser, R. ;

Moeller, E. ;

Ritter, M. ;

Vuocolo, S. ;

Luxembourg, A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (08) :711-723

[6] Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women [J].

Paovonen, J. ;

Naud, P. ;

Salmeron, J. ;

Wheeler, C. M. ;

Chow, S-N ;

Apter, D. ;

Kitchener, H. ;

Castellsague, X. ;

Teixeira, J. C. ;

Skinner, S. R. ;

Hedrick, J. ;

Jaisamrarn, U. ;

Limson, G. ;

Garland, S. ;

Szarewski, A. ;

Romanowski, B. ;

Aoki, F. Y. ;

Schwarz, T. F. ;

Poppe, W. A. J. ;

Bosch, F. X. ;

Jenkins, D. ;

Hardt, K. ;

Zahaf, T. ;

Descamps, D. ;

Struyf, F. ;

Lehtinen, M. ;

Dubin, G. .

LANCET, 2009, 374 (9686) :301-314

← 1 →